Shalby Ltd
Shalby Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Shalby MedTech expects sustained growth driven by increased implant sales and robotic rental income. Stand-alone EBITDA margin is expected to improve by 200 to 300 basis points from current 19.5%, indicating sustainable margin growth for FY '26 and beyond.
From Shalby Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Shalby MedTech expects sustained growth driven by increased implant sales and robotic rental income.
- Robust domestic volume growth and improved channel partner engagement are key revenue drivers.
- Expansion of product portfolio with surgeon-friendly implants and new product developments by R&D teams in India and the U.S.
- Reduction in COGS by 9% YoY and supply chain and distribution efficiencies aiming for 15-20% cost reduction.
- Capacity improvements expected to be realized by Q3-Q4 FY '26 with existing plant capacity sufficient for next 5 years.
- Growth supported by new technology introduction (robotics in general surgery, oncology, neurosurgery).
- Geographic growth focused on India, U.S., Southeast Asia, and developing markets, not northeastern region currently.
- Hospital occupancy projected to increase by 4-5 percentage points in upcoming quarters, supporting revenue growth.
2 more points from Shalby Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Shalby Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Q2 FY '26 capex spend was about INR 70 crores for the first 6 months, largely on robotic and oncology machines (~INR 50 crores).
- Purchased 5 orthopedic robots; planning to acquire robots for general surgery, onco surgery, and neurosurgery (starting with SSI Mantra, then da Vinci).
- Investment made in radiotherapy machines; major orthopedic surgical equipment investments completed.
- Adding 2 new linac bunkers in Surat and Ahmedabad, expected to start contributing revenue from Q4 onwards.
- Installation of an additional PET/CT scan machine at Naroda, Ahmedabad planned in next quarter or fiscal year.
- Focus on capacity improvement, especially in implant manufacturing, to meet demand for next 5 years.
2 more points from Shalby Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Shalby Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Shalby Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shalby Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Maitreya Medicare Ltd (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medica.'s Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Arthneeti Pro · Annual
Shalby Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shalby Ltd Q2 FY26 results?
Shalby MedTech expects sustained growth driven by increased implant sales and robotic rental income. Stand-alone EBITDA margin is expected to improve by 200 to 300 basis points from current 19.5%, indicating sustainable margin growth for FY '26 and beyond.
What is Shalby Ltd share price analysis?
Shalby Ltd currently shows a neutral. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shalby Ltd planning capital expenditure?
Q2 FY '26 capex spend was about INR 70 crores for the first 6 months, largely on robotic and oncology machines (~INR 50 crores). - Purchased 5 orthopedic robots; planning to acquire robots for general surgery, onco surgery, and neurosurgery (starting with SSI Mantra, then da Vinci). - Investment made in radiotherapy machines; major orthopedic surgical equipment investments completed. - Adding 2 new linac bunkers in Surat and Ahmedabad, expected to start contributing revenue from Q4 onwards. - Installation of an additional PET/CT scan machine at Naroda, Ahmedabad planned in next quarter or fiscal year. - Focus on capacity improvement, especially in implant manufacturing, to meet demand for next 5 years. - Set up new R&D offices in India and the U.S.
Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.